The National Health and Medical Research Council (NHMRC) of Australia has released its preliminary advice for treating transgender youth under 18 years old reaffirming permission for doctors to prescribe puberty blockers to gender diverse patients.
The public comment period on this avenue of gender-affirming care will conclude in January 2027. More expansive guidelines are expected in 2028.
“Healthcare professionals should respect the young person’s best interests, autonomy, dignity, privacy, and their capacity to be involved in decisions about their care and the use or disclosure of personal information (e.g. preferred names and pronouns),” the advice paper reads.
“Shared decisions about the use of puberty suppressants should be informed by the provision of appropriate information to the young person and their parents or carers, a comprehensive health assessment, multidisciplinary input, and regular monitoring.”
Equality Australia CEO Anna Brown said this guidance “reinforces that the care trans young people are receiving in Australia today is grounded in evidence, informed by clinical expertise and guided by the individual needs of young people.” However, the recommendations are not a legal mandate. Individual states within Australia—like Queensland and the Northern Territory—have their own regionalized bans.
Like the U.S., Australia has seen its own wave of anti-trans activism, in no small part funded by the Conservative Political Action Conference (CPAC), which is a conservative American organization. Genspect, the Society for Evidence-based Gender Medicine, and Therapy First, all of which are in the pseudoscience arm of America’s own anti-trans infrastructure, have also been key players in Australia’s anti-trans renaissance.
“Trans young people in Queensland are being denied access to healthcare that Australia’s peak medical research body recognises as an appropriate treatment option,” Brown said. “No young person’s access to clinically appropriate healthcare should depend on which state they live in.”
The document states that puberty suppressants are just one possible component of care—alongside potential interventions like psychosocial support and hormone replacement therapy (HRT). It also stipulates that “it is not necessary to wait until a young person is distressed before providing care.”
The advice, though interim, is a valuable indicator of support for trans people and sound science on the global stage. Right-wing movements have captured governing and health institutions in a critical mass of the English-speaking world, including in the United States, Canada, and especially the United Kingdom.
For example, the U.S. Department of Health and Human Services issued a several-hundred-page pseudoscience report decrying gender-affirming care for trans youth, much of which was sourced from a similar effort in the United Kingdom called the Cass Review. There, new prescriptions for puberty blockers are banned indefinitely thanks to the anti-trans medical activism of TERF propagandists such as J.K. Rowling. New patients can only access puberty blockers to treat dysphoria through the PATHWAYS clinical trial, which a court cleared to proceed this summer after a months-long pause.
In October, the Professional Association for Transgender Health Aotearoa (PATHA) in New Zealand successfully challenged its own puberty blocker ban in court.
In areas where access to puberty blockers has been curtailed, trans youth may have no choice but to go through a puberty that develops secondary sex characteristics at odds with the identity some have lived in for years. Puberty blockers are a gold standard for gender-affirming care for youth at the cusp of puberty. Among other things, they can give families time to wait and see how a child’s gender identity continues to develop.
The public consultation period commenced on Nov. 16, and it will end on Jan. 18, 2027. The public comment portal for the full guidelines—which will include other treatment methods, such as the use of hormone replacement therapy or gender-affirming procedures like “top surgery”—is expected to open in early 2028.
“Many of the families we support tell us they feel like they are constantly having to justify their child’s existence, their child’s identity, or their child’s right to healthcare,” Transcend CEO Susanne Prosser said.
“These guidelines are important because they recognise trans and gender diverse children and young people as deserving of the same evidence-based, respectful healthcare as every other child.”
The NHMRC says as much, cementing its clinical recommendations as a declaration of values as well. “Gender diversity is not inherently pathological or negative,” the advice says. “It is important to recognise the young person’s inherent dignity and worth, and to avoid undermining or pathologising their gender identity or experiences.”
The NHMRC’s full working statement on puberty blockers can be seen here.




This makes my soul sing 👇
“Gender diversity is not inherently pathological or negative,” the advice says. “It is important to recognise the young person’s inherent dignity and worth, and to avoid undermining or pathologising their gender identity or experiences.”
And aren't all the Aussie 'phobes squawking about it!
Thank you for the reporting, Baum